Efficacy and Safety of a Highly Bioavailable Curcumin Formulation in Modulating Outcomes of Mild Knee Osteoarthritis: Multi-Centric, Randomized, Double-Blind, Placebo-Controlled Study
Journal of Orthopedic Research and Therapy · 2023
DOI: 10.29011/2575-8241.001303 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Orthopedic Research and Therapy, 2023.
Abstract (Originalsprache)
Background
Osteoarthritis (OA) is a degenerative disease of joints affecting aging population worldwide with significant unmet medical needs.Here we report efficacy and safety of a highly bioavailable curcumin formulation, Curcuwin Ultra+ (CU+) in subjects with mild knee OA.
Methods
Forty-five subjects each for CU+ 250 mg, CU+ 500 mg, and placebo groups with mild knee OA were randomized in a multi-centric, double-blind, parallel, placebo-controlled study with a treatment period of 84 days.A range of primary and secondary endpoints were assessed at baseline, day 5, 28, 56 and 84.The trial was prospectively registered on Clinical Trials Registry -India (CTRI/2021/10/037187) dated 08/10/2021.
Results
A significant improvement (p
Zitieren
APA
(2023). Efficacy and Safety of a Highly Bioavailable Curcumin Formulation in Modulating Outcomes of Mild Knee Osteoarthritis: Multi-Centric, Randomized, Double-Blind, Placebo-Controlled Study. Journal of Orthopedic Research and Therapy. https://doi.org/10.29011/2575-8241.001303
Vancouver
Efficacy and Safety of a Highly Bioavailable Curcumin Formulation in Modulating Outcomes of Mild Knee Osteoarthritis: Multi-Centric, Randomized, Double-Blind, Placebo-Controlled Study. Journal of Orthopedic Research and Therapy. 2023. doi:10.29011/2575-8241.001303
BibTeX
@article{euvimed2023,
title = {Efficacy and Safety of a Highly Bioavailable Curcumin Formulation in Modulating Outcomes of Mild Knee Osteoarthritis: Multi-Centric, Randomized, Double-Blind, Placebo-Controlled Study},
journal = {Journal of Orthopedic Research and Therapy},
year = {2023},
doi = {10.29011/2575-8241.001303}
}
EUVIMED